Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 6:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 36 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cataplexy Clear all
Completed Phase 3 Interventional
View directory record Official record
Conditions
Narcolepsy, Cataplexy, Excessive Daytime Sleepiness
Interventions
AXS-12 (reboxetine), Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
15 Years to 75 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
24
States / cities
Phoenix, Arizona • Boulder, Colorado • Colorado Springs, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced May 21, 2026, 6:54 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Narcolepsy With Cataplexy
Interventions
Xyrem
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
7 Years to 17 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
17
States / cities
Long Beach, California • Orange, California • Redwood City, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2019 · Synced May 21, 2026, 6:54 PM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
Narcolepsy Type 1
Interventions
TAK-861, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
16 Years to 70 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
15
States / cities
Phoenix, Arizona • Redwood City, California • Santa Ana, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2025 · Synced May 21, 2026, 6:54 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Narcolepsy With Cataplexy
Interventions
JZP-258, Placebo
Drug · Other
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
12
States / cities
Orange, California • Stanford, California • Boulder, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2020 · Synced May 21, 2026, 6:54 PM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Narcolepsy, Narcolepsy Type 1, Narcolepsy With Cataplexy, Narcolepsy Type 2, Narcolepsy Without Cataplexy
Interventions
Imagery rehearsal therapy, Targeted dream control
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 11, 2024 · Synced May 21, 2026, 6:54 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Narcolepsy With Cataplexy, Narcolepsy, Narcolepsy Without Cataplexy
Interventions
Mazindol
Drug
Lead sponsor
NLS Pharmaceutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
22
States / cities
Birmingham, Alabama • Redwood City, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2023 · Synced May 21, 2026, 6:54 PM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Narcolepsy Type 1 (NT1), Narcolepsy With Cataplexy
Interventions
TAK-861, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
16 Years to 70 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
11
States / cities
Redwood City, California • Brandon, Florida • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced May 21, 2026, 6:54 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2)
Interventions
TAK-994, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
36
States / cities
Alabaster, Alabama • Phoenix, Arizona • Bellflower, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2024 · Synced May 21, 2026, 6:54 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Narcolepsy Type 1 (NT 1)
Interventions
TAK-994, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
35
States / cities
Alabaster, Alabama • Phoenix, Arizona • Bellflower, California + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 25, 2023 · Synced May 21, 2026, 6:54 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Narcolepsy Type 1
Interventions
ALKS 2680, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
29
States / cities
Los Angeles, California • Redwood City, California • San Francisco, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced May 21, 2026, 6:54 PM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Narcolepsy Type 1
Interventions
ALKS 2680 Dose 1, ALKS 2680 Dose 2, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
9
States / cities
Brandon, Florida • Macon, Georgia • Lansing, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced May 21, 2026, 6:54 PM EDT
Terminated Not applicable Interventional Results available
View directory record Official record
Conditions
Hypersomnia
Interventions
Transcranial Direct Current Stimulation, Sham stimulation
Device
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 70 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 24, 2021 · Synced May 21, 2026, 6:54 PM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
Narcolepsy, Cataplexy, Excessive Daytime Somnolence, Sleep Disorder, Sleep Disturbance, Sleep Wake Disorders
Interventions
FT218
Drug
Lead sponsor
Avadel
Industry
Eligibility
16 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
27
States / cities
Birmingham, Alabama • Redwood City, California • Santa Ana, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced May 21, 2026, 6:54 PM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
Narcolepsy, Cataplexy, Excessive Daytime Sleepiness
Interventions
AXS-12 (reboxetine), Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
15 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
47
States / cities
Alabaster, Alabama • Peoria, Arizona • Phoenix, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced May 21, 2026, 6:54 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Narcolepsy
Interventions
SEP363856, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
6
States / cities
Orange, California • St. Petersburg, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced May 21, 2026, 6:54 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Narcolepsy, Cataplexy Narcolepsy, Excessive Sleepiness
Interventions
AXS-12 (Reboxetine), Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
14
States / cities
Birmingham, Alabama • Alameda, California • Santa Ana, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced May 21, 2026, 6:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Narcolepsy With or Without Cataplexy
Interventions
APD916
Drug
Lead sponsor
Arena Pharmaceuticals
Industry
Eligibility
18 Years to 45 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 1, 2010 · Synced May 21, 2026, 6:54 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Narcolepsy, Sleep Apnea, Obstructive, Sleep Apnea Syndromes, Shift-Work Sleep Disorder
Interventions
CEP-10953 (Armodafinil)
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 65 Years
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
41
States / cities
Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced May 21, 2026, 6:54 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Narcolepsy Type 2
Interventions
TAK-360, Placebo
Drug · Other
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 70 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
12
States / cities
Redwood City, California • Santa Ana, California • Colorado Springs, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced May 21, 2026, 6:54 PM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Hypersomnia, Primary Hypersomnia, Idiopathic Hypersomnia, Narcolepsy Without Cataplexy
Interventions
Flumazenil
Drug
Lead sponsor
Lynn Marie Trotti
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced May 21, 2026, 6:54 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Narcolepsy, Excessive Daytime Sleepiness, Cataplexy Narcolepsy
Interventions
mazindol extended release, Placebo
Drug
Lead sponsor
NLS Pharmaceutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
22
States / cities
Birmingham, Alabama • Redwood City, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2022 · Synced May 21, 2026, 6:54 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Hypersomnia, Idiopathic Hypersomnia, Narcolepsy
Interventions
Clarithromycin followed by placebo, Placebo then Clarithromycin
Drug
Lead sponsor
Lynn Marie Trotti
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced May 21, 2026, 6:54 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Narcolepsy Without Cataplexy, Idiopathic Hypersomnia, Narcolepsy With Cataplexy
Interventions
Clarithromycin, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 60 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced May 21, 2026, 6:54 PM EDT
Completed Not applicable Interventional Results available
View directory record Official record
Conditions
Narcolepsy, Narcolepsy Without Cataplexy, Narcolepsy With Cataplexy
Interventions
Brief MBI, Standard MBI, Extended MBI
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 100 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced May 21, 2026, 6:54 PM EDT